 |
|
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clin Mol Hepatol. 2023;29(4):909-923. Published online 2023 May 25 DOI: https://doi.org/10.3350/cmh.2023.0114
|
|
Citations to this article as recorded by
 The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma
Beom Kyung Kim
Gut and Liver.2024; 18(1): 3. CrossRef Hepatocellular Carcinoma: Advances in Systemic Therapy
Insija Ilyas Selene, Merve Ozen, Reema A. Patel
Seminars in Interventional Radiology.2024; 41(01): 056. CrossRef Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis
YiFeng Liang, LiMing Gan, DeJin Zeng, LangHua Lin, ZheKun Xiong, FangLian Liao, ALing Wang
Clinical and Translational Oncology.2024; 26(10): 2652. CrossRef Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells
Zengbin Wang, Linqing Wu, Yu Zhou, Zhong Chen, Tao Zhang, Hong Wei, Zhihong Wang
Frontiers in Pharmacology.2024;[Epub] CrossRef Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study
Saikang Tang, Yingming Gao, Xue Yan, Weihua Zhi, Yue Han
Frontiers in Oncology.2024;[Epub] CrossRef Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma
Ji Kim, Young Kim, Hee-Chul Nam, Chang-Wook Kim, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Ho Jong Chun, Jung Oh, Suho Kim, Sung Lee, Pil Sung
Oncology Letters.2024;[Epub] CrossRef Hepatocellular carcinoma and AIM2: Therapeutic potential through regulation of autophagy and macrophage polarization
Shuangshuang Xie, Cuiyun Wang, Xiaoyan Liu, Cheng Li, Jinhong Yu, Shumin Ma, Qiang Li, Wenjun Du
Immunity, Inflammation and Disease.2024;[Epub] CrossRef Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma
Ji Won Han, Min Woo Kang, Soon Kyu Lee, Hyun Yang, Ji Hoon Kim, Jae-Sung Yoo, Hee Sun Cho, Eun Ji Jang, Deok Hwa Seo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung
Liver Cancer.2024; : 1. CrossRef The interdisciplinary approach to investigate bona fide agent(s) in flavonoids or alkaloids in treating HCC
Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Goo-Hyun Kwon, Dong Joon Kim, Ki-Tae Suk
Artificial Cells, Nanomedicine, and Biotechnology.2024; 52(1): 500. CrossRef Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Clinical and Molecular Hepatology.2024; 30(4): 807. CrossRef Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma
Nan Yi, Lingyun Zhang, Xiangbo Huang, Jilei Ma, Jian Gao
Cellular Oncology.2024;[Epub] CrossRef Current progress of pig models for liver cancer research
Luyao Wang, Yuexian Piao, Fucheng Guo, Jiarui Wei, Yurong Chen, Xiangpeng Dai, Xiaoling Zhang
Biomedicine & Pharmacotherapy.2023; 165: 115256. CrossRef
|